Ultra-LEAF™ Purified anti-mouse CD269 (BCMA) Antibody, CD269, A16124J,BioLegend,943603

Mouse TNFRSF17-Fc chimera is a type I attached membrane protein of 185 amino acids, which possesses a conserved motif of six cysteines in the N-terminal. It is consistent with the formation of a cysteine repeat motif found in the extracellular domain of TNFRs, and is 62% identical to the human receptor. The overexpression of TNFRSF17-Fc chimera in 293E cells activates NF-κB, Elk-1, the c-Jun N-terminal kinase, and the p38 mitogen-activated protein kinase. After its association with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3. Soluble forms of TACI (TNFRSF13B) and TNFRSF17-Fc chimera bind to BAFF (TNFSFL13B) and APRIL (TNFSFL13A). The interaction of TNFRSF17-Fc chimera to APRIL has higher affinity than the TNFRSF17-BAFF interaction. Analysis of BCMA knockout mice (BCMA−/−) showed no differences in the steady-state frequencies or composition of peripheral B cell subsets (immature, marginal zone, follicular, B1). BCMA expression is upregulated on PBMCs from mice that develop a Sjogren’s-like syndrome, patients with Sjogren’s syndrome, with rheumatoid arthritis, and on B cells from SLE patients. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-κB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-κB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.